Axon Ventures

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Cradle Genomics, Inc. specializes in fetal genetic analysis and pregnancy health screening solutions, focusing on non-invasive prenatal testing (NIPT) to provide comprehensive insights at the earliest stages of pregnancy. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company has developed a platform that analyzes genetic material from fetal cells collected during a first trimester visit. This approach allows pregnant women to receive critical information about their health and the health of their developing fetus without any risk. Cradle Genomics aims to empower expectant parents with knowledge that can guide their decisions throughout the pregnancy journey.

Edico Genome Inc. specializes in the development of bioinformatics processor chips focused on DNA analysis. The company's primary product, the DRAGEN platform, utilizes a field-programmable gate array to accelerate genome pipeline algorithms, including tasks such as BCL conversion, mapping, alignment, and variant calling. This technology enhances the efficiency of analyzing next-generation sequencing data, facilitating healthcare institutions in identifying connections between DNA sequence variations and human diseases. Founded in 2013 and headquartered in La Jolla, California, Edico Genome operates as a subsidiary of Illumina, Inc. since May 2018.

Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company is known for its Obalon Balloon System, which includes a swallowable capsule containing an inflatable balloon, a navigation console for tracking balloon placement, a semi-automated inflation device, and a disposable gas canister. This system aims to assist patients in achieving weight loss through a non-surgical approach. Founded in 2008, Obalon emphasizes collaboration with clinicians and a commitment to rigorous testing to ensure safety and performance in its products. As of early 2020, the company operated three retail treatment centers in California, reflecting its focus on providing accessible solutions for individuals struggling with obesity.

Edico Genome Inc. specializes in the development of bioinformatics processor chips focused on DNA analysis. The company's primary product, the DRAGEN platform, utilizes a field-programmable gate array to accelerate genome pipeline algorithms, including tasks such as BCL conversion, mapping, alignment, and variant calling. This technology enhances the efficiency of analyzing next-generation sequencing data, facilitating healthcare institutions in identifying connections between DNA sequence variations and human diseases. Founded in 2013 and headquartered in La Jolla, California, Edico Genome operates as a subsidiary of Illumina, Inc. since May 2018.